{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:51:42Z","timestamp":1791921102059,"version":"4.3.4"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010099","name":"Institute of Organic Chemistry and Biochemistry Czech Academy of Sciences","doi-asserted-by":"publisher","award":["RVO 61388963"],"award-info":[{"award-number":["RVO 61388963"]}],"id":[{"id":"10.13039\/501100010099","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.ejmech.2026.119366","type":"journal-article","created":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T14:55:24Z","timestamp":1790434524000},"page":"119366","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P1","title":["Yohimbine derivatives containing carboxylic acid and ester bioisosteres as potent ADRA2A antagonists"],"prefix":"10.1016","volume":"321","author":[{"given":"Artem","family":"Chayka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"\u010cesnek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Ku\u017emov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaroslav","family":"Koz\u00e1k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6890-6464","authenticated-orcid":false,"given":"Karel","family":"Chalupsk\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Dvo\u0159\u00e1kov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzana","family":"Osifov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4495-0070","authenticated-orcid":false,"given":"Martin","family":"Dra\u010d\u00ednsk\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Mertl\u00edkov\u00e1-Kaiserov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4654-679X","authenticated-orcid":false,"given":"Zlatko","family":"Janeba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.119366_bib1","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.gene.2018.05.078","article-title":"The ADRA2A rs553668 variant is associated with type 2 diabetes and five variants were associated at nominal significance levels in a population-based case-control study from Mexico City","volume":"669","author":"Totomoch-Serra","year":"2018","journal-title":"Gene"},{"key":"10.1016\/j.ejmech.2026.119366_bib2","article-title":"Genetic and functional analysis of Raynaud's syndrome implicates loci in vasculature and immunity","volume":"4","author":"Tervi","year":"2024","journal-title":"Cell Genom."},{"key":"10.1016\/j.ejmech.2026.119366_bib3","doi-asserted-by":"crossref","first-page":"6156","DOI":"10.1038\/s41467-023-41876-5","article-title":"ADRA2A and IRX1 are putative risk genes for Raynaud's phenomenon","volume":"14","author":"Hartmann","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119366_bib4","first-page":"209","article-title":"Rauwolfia serpentina. The components and their pharmacological effect","volume":"126","author":"van Noppen","year":"1955","journal-title":"Chem. Zentralbl."},{"key":"10.1016\/j.ejmech.2026.119366_bib5","doi-asserted-by":"crossref","unstructured":"P.W. Danckwortt, P. Luy, Alkaloids of yohimbehe barkArch. Pharm. Ber. Dtsch. Pharm. Ges. 262, 81\u2013104.","DOI":"10.1002\/ardp.19242620202"},{"key":"10.1016\/j.ejmech.2026.119366_bib6","doi-asserted-by":"crossref","unstructured":"N.R. Jabir, C.K. Firoz, T.A. Zughaibi, et al.,A literature perspective on the pharmacological applications of yohimbine, Ann. Med. 54 (2022) 2861\u20132875.","DOI":"10.1080\/07853890.2022.2131330"},{"key":"10.1016\/j.ejmech.2026.119366_bib7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/BF00592678","article-title":"Autonomic and psychic effects of yohimbine hydrochloride","volume":"2","author":"Holmberg","year":"1961","journal-title":"Psychopharmacologia"},{"key":"10.1016\/j.ejmech.2026.119366_bib8","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/BF02455991","article-title":"The pharmacokinetics of yohimbine in man","volume":"32","author":"Owen","year":"1987","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119366_bib9","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0378-4347(92)80041-N","article-title":"Determination of yohimbine and its two hydroxylated metabolites in humans by high-performance liquid chromatography and mass spectral analysis","volume":"574","author":"Le Verge","year":"1992","journal-title":"J. Chromatogr. B Biomed. Sci. Appl."},{"key":"10.1016\/j.ejmech.2026.119366_bib10","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/BF00315421","article-title":"Yohimbine bioavailability in humans","volume":"39","author":"Guthrie","year":"1990","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119366_bib11","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0928-0987(99)00046-9","article-title":"Biopharmaceutics and metabolism of yohimbine in humans","volume":"9","author":"Le Corre","year":"1999","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejmech.2026.119366_bib12","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s40262-020-00862-6","article-title":"Oral yohimbine as a new probe drug to predict CYP2D6 activity: results of a fixed-sequence phase I trial","volume":"59","author":"Vay","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2026.119366_bib14","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s00706-025-03352-2","article-title":"Yohimbine stability: analysis of its several decades-old pharmaceutical products and forced degradation study","volume":"156","author":"Nesm\u011br\u00e1k","year":"2025","journal-title":"Monatsh. Chem."},{"key":"10.1016\/j.ejmech.2026.119366_bib15","first-page":"134","article-title":"Determination of hydrolysis parameters of yohimbine HCl at neutral and slightly acidic medium","volume":"7","author":"Awad","year":"2015","journal-title":"Int. J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.ejmech.2026.119366_bib16","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1021\/acs.jmedchem.5b01963","article-title":"Structure property relationships of carboxylic acid isosteres","volume":"59","author":"Lassalas","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119366_bib17","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1016\/j.bmc.2016.05.010","article-title":"Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy","volume":"24","author":"Hoshi","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119366_bib18","series-title":"2024; Chemical Computing Group ULC, 910-1010 Sherbrooke St. W., Montreal, QC H3A 2R7, Canada","year":"2025"},{"key":"10.1016\/j.ejmech.2026.119366_bib19","doi-asserted-by":"crossref","first-page":"10135","DOI":"10.1021\/acs.jmedchem.4c00323","article-title":"Structure-based drug design of ADRA2A antagonists derived from yohimbine","volume":"67","author":"Chayka","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119366_bib20","doi-asserted-by":"crossref","first-page":"4715","DOI":"10.1039\/C9CC00720B","article-title":"Synthesis of chiral nine and twelve-membered cyclic polyamines from natural building blocks","volume":"55","author":"Muntener","year":"2019","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2026.119366_bib21","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1021\/op8003184","article-title":"Process development of a potent bradykinin 1 antagonist","volume":"13","author":"Menzel","year":"2009","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.ejmech.2026.119366_bib22","doi-asserted-by":"crossref","first-page":"8036","DOI":"10.1039\/C4OB00854E","article-title":"An experimental and theoretical study of reaction mechanisms between nitriles and hydroxylamine","volume":"12","author":"V\u00f6r\u00f6s","year":"2014","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2026.119366_bib23","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1021\/acs.jmedchem.9b01465","article-title":"Investigation of the adrenergic and opioid binding affinities, metabolic stability, plasma protein binding properties, and functional effects of selected indole-based kratom alkaloids","volume":"63","author":"Obeng","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119366_bib24","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/j.1476-5381.1993.tb13488.x","article-title":"Alpha 2-adrenoceptor antagonist potencies of two hydroxylated metabolites of yohimbine","volume":"108","author":"Berlan","year":"1993","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119366_bib25","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1124\/dmd.117.077040","article-title":"Clearance prediction methodology needs fundamental improvement: trends common to rat and human hepatocytes\/microsomes and implications for experimental methodology","volume":"45","author":"Wood","year":"2017","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejmech.2026.119366_bib26","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/BF00182736","article-title":"The pharmacokinetic properties of yohimbine in the conscious rat","volume":"337","author":"Hubbard","year":"1988","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.ejmech.2026.119366_bib27","first-page":"304","article-title":"Distribution and metabolism of tritiated yohimbine in mice","volume":"194","author":"Ho","year":"1971","journal-title":"Arch. Int. Pharmacodyn. Ther."},{"key":"10.1016\/j.ejmech.2026.119366_bib28","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","article-title":"PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel","volume":"99","author":"Zhang","year":"2010","journal-title":"Comput. Methods Progr. Biomed."},{"key":"10.1016\/j.ejmech.2026.119366_bib29","article-title":"Crystal structures of the alpha2A adrenergic receptor in complex with an antagonist RSC","author":"Qu","year":"2019","journal-title":"Natl. Nat. Sci. Found. China"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426008111?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426008111?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:35:39Z","timestamp":1791920139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426008111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":28,"alternative-id":["S0223523426008111"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119366","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Yohimbine derivatives containing carboxylic acid and ester bioisosteres as potent ADRA2A antagonists","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119366","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119366"}}